Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 3/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831882 | 0.94 | HSD11B1 (0.46) | HSD11B1EPHX2SCN9ANMT1LMNA | |
| SCHEMBL5831671 | 0.86 | HSD11B1 (0.46) | HSD11B1SCN9ANMT1MAPK1 | |
| SCHEMBL3621175 | 0.85 | HSD11B1 (0.54) | HSD11B1EPHX2RORCMAPTLMNA | |
| SCHEMBL5830665 | 0.84 | HSD11B1 (0.39) | HSD11B1EPHX2NMT1PFKFB3 | |
| SCHEMBL3252502 | 0.84 | HSD11B1 (0.39) | HSD11B1EPHX2SCN9ARORCNMT1 | |
| SCHEMBL5830640 | 0.84 | HSD11B1 (0.39) | HSD11B1EPHX2SCN9ANMT1MAPT | |
| SCHEMBL5830780 | 0.82 | SCN9A (0.34) | HSD11B1SCN9ALMNA | |
| SCHEMBL5831063 | 0.82 | HSD11B1 (0.44) | HSD11B1SCN9A | |
| SCHEMBL6628472 | 0.81 | HSD11B1 (0.38) | HSD11B1EPHX2RORCNMT1PFKFB3 | |
| SCHEMBL27603916 | 0.81 | SCN9A (0.34) | HSD11B1EPHX2SCN9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074788-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-07-11 | — | — | US | claimed |
| EP-1461327-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | claimed |
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2003044000-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | claimed |
| US-7074788-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-07-11 | — | — | US | disclosed |
| EP-1461327-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003044000-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | CPT1A, HSD11B1, CES1 | HSD11B1 2/4885EPHX2 1669/4885SCN9A 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.